


GOG 263


PI; Sang Young Ryu, MD

Randomized Phase III Clinical Trial of Adjuvant Radiation vs Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy



Treatment of Intermediate Risk Cx ca.

(Ryu et al., IJROBP 2009)



GOG 263

- **Primary endpoint**
 - **3 year recurrence free survival**
 - 6.3% (87% to 93.3%)
 - 6.3% increase of RFS
 - Total sample size: 534

Eligibility Criteria

(GOG 263=GOG 92)

TABLE 1
Eligibility Criteria

CLS ^a	Stromal invasion	Tumor size
Positive	Deep 1/3	Any
Positive	Middle 1/3	≥2 cm
Positive	Superficial 1/3	≥5 cm
Negative	Deep or middle 1/3	≥4 cm

^a Capillary lymphatic space tumor involvement.

GOG 263

- Cervix cancer after RH
 - > If LVSI(+)
 - > or If > 2/3 cervical wall
 - > or If > 2cm

Then, **80% provability** of GOG 263 candidate.

Accrual of GOG 263

